CivicaScript LLC, a nonprofit focused on bringing low-cost generic medicines to US patients, announced on Thursday that it has launched its droxidopa in the United States.
Droxidopa is intended for the treatment in adults of certain types of orthostatic dizziness, light-headedness or the 'feeling that you are about to black out'.
The company will be providing droxidopa 300mg capsules for sale to pharmacies from 10 April, priced at USD132 per bottle of 90 capsules. It has been recommended that pharmacies charge patients no more than USD153 per bottle.
CivicaScript will offer 100 mg, 200 mg and 300 mg strengths of droxidopa capsules.
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules
Upsher-Smith launches generic version of Ciprodex ear drop suspension
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
Breckenridge Pharmaceutical partners with sterile injectable manufacturer Maiva Pharma
Breckenridge Pharmaceutical launches Pomalidomide Capsules in US market